Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CABA-DOC: Patient Preference Between Cabazitaxel and Docetaxel in First-line mCRPC
NCT02044354Phase 3Completed
- Sponsor
- Gustave Roussy
- Start
- May 2014
- Primary completion
- Apr 2017
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 3 trial of cabazitaxel, docetaxel in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Gustave Roussy. Started May 2014; status: completed.
02
Drugs
cabazitaxeldocetaxel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02044354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02044354.